Home » Newsletters » BioWorld Science

BioWorld Science

July 30, 2007

View Archived Issues

Kissei enters development agreement with Nuon Therapeutics for Rizaben

First milestone investment planned by Amorfix-Biogen Idec partnership

Oswaldo Cruz Foundation and Genzyme form research collaboration

Inovio, NCI and IAVI collaborate to evaluate DNA vaccine delivery technology

Fosalvudine tidoxil monotherapy is safe and effective in treatment-naive HIV-infected patients

Maraviroc+optimized antiretroviral background therapy safe and effective:MOTIVATE 1 and 2 trials

Advanced Magnetics changes to AMAG Pharmaceuticals

ChemoCentryx earns milestone payment from GlaxoSmithKline

Favorable profile emerges for second-generation HIV-1 maturation inhibitor from Panacos

Update on Biopure's phase II study of Hemopure

CHMP grants positive opinion of expanded label of Cubicin

GMI-1070: GlycoMimetics' lead pan-selectin antagonist drug candidate for sickle cell crisis

First characterization of a selective nonpeptide formyl peptide receptor-like 1 antagonist

Siemens to acquire Dade Behring

ZARS begins phase III trial of ThermoProfen for osteoarthritis

CytoDyn reports results of DNA vaccine effectiveness comparative study

Tranzyme begins phase IIb trial of TZP-101 for management of POI

Kuvan receives priority review status from FDA

Novel agents for the treatment of endocrine disorders

Gruenenthal presents analgesic agents targeting monoamine uptake and mu receptors

New antiinfectives disclosed in patent literature

Merck to acquire NovaCardia to boost clinical pipeline of cardiovascular drug candidates

Athersys begins phase I trial for ATHX-105 for treatment of obesity

Patient treatment begins in phase I/II trial of MDV-3100 in hormone-refractory prostate cancer

Vyvanse now available in the U.S, for ADHD

EMEA grants orphan drug status to Active Biotech's cancer treatment Anyara

OctoPlus obtains full rights to PolyActive drug delivery technology from IsoTis

Eszopiclone filed for approval in EU and licensed to Eisai in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...